NICE plans to lift a restriction on 3 Alzheimer's drugs

10/6/2010 | Reuters

The U.K. National Institute for Health and Clinical Excellence issued a draft guidance that would reverse a 2006 decision to restrict patient access to certain Alzheimer's disease drugs. The agency recommended that Eisai and Pfizer's Aricept, Novartis' Exelon and Shire's Reminyl be covered by the National Health Service for patients with mild and moderate Alzheimer's.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA